Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Sio Gene Therapies Inc. | axovantexhibit322.htm |
| EX-32.1 - EXHIBIT 32.1 - Sio Gene Therapies Inc. | axovantexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - Sio Gene Therapies Inc. | axovantexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - Sio Gene Therapies Inc. | axovantexhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 - Sio Gene Therapies Inc. | axovantexhibit231.htm |
| EX-21.1 - EXHIBIT 21.1 - Sio Gene Therapies Inc. | axovantexhibit211.htm |
| EX-10.15 - EXHIBIT 10.15 - Sio Gene Therapies Inc. | axovantexhibit1015.htm |
| EX-10.13 - EXHIBIT 10.13 - Sio Gene Therapies Inc. | axovantexhibit1013.htm |
| EX-10.12 - EXHIBIT 10.12 - Sio Gene Therapies Inc. | axovantexhibit1012.htm |
| 10-K - 10-K - Sio Gene Therapies Inc. | axovant3311710k.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-215387) and Form S-8 (No. 333-206300 and No. 333-215386) of Axovant Sciences Ltd. of our report dated June 6, 2016 relating to the financial statements, which appears in this Form 10‑K.
/s/PricewaterhouseCoopers LLP
Florham Park, NJ
June 13, 2017